ello, everyone, and how are you today? We are just fine, thank you, now that the Pharmalot campus has settled down a bit. The shortest person has departed for the local schoolhouse and the official mascots are happily snoozing away. As for us, we are foraging, as always, for interesting items and digging in for another busy day. No doubt, you can relate. So time to get cracking. Here are some tidbits to help you along. Hope your day goes well and do stay in touch …

As generic competition nears for its Advair treatment for asthma and chronic obstructive pulmonary disease, GlaxoSmithKline has been making payers an “exploding offer” of a 20 percent or more discount, according to Bernstein analyst Ronny Gal. The deals cover all of 2017, he adds. As a result, he believes market prices may not drop sharply once generics arrive as some have expected.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy